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Abstract. 
 
We prepared several monoclonal antibodies 
(mAbs) specific for the NH
 
2
 
- and COOH-terminal re-
gions of the DNA helicase (WRN helicase) responsible 
for WernerÕs syndrome known as a premature aging 
disease. With these antibodies, we detected by immu-
noblot analysis the endogenous WRN helicase of a rel-
ative mass of 180 kD in several lines of cultured cells, 
but not in patient cells with a defined mutation. Immu-
nocytochemical staining of proliferating fibroblasts and 
tumor cells showed that the major part of WRN heli-
case is in the nucleoplasm and not in the nucleolus. 
Similar experiments with a rat mAb specific to the 
mouse homologue of human WRN helicase yielded an 
identical conclusion. Although this nucleoplasmic stain-
ing was evident in cells in interphase, the condensed 
chromatin structure in metaphase was not stained by 
the same mAbs, suggesting that WRN helicases exist 
perhaps in a soluble form or bound to the unfolded 
chromatin structure. From quantitative immunoblot 
analysis, higher levels of WRN helicase were observed 
in all transformed cells and tumor cells examined than 
those of normal cells. The expression of WRN helicase 
was enhanced consistently in fibroblasts and B-lympho-
blastoid cells by transformation with SV-40 and Ep-
stein-Barr virus, respectively, suggesting that rapidly 
proliferating cells require a high copy numbers of WRN 
helicase.
Key words: WernerÕs syndrome ¥ RecQ DNA heli-
case ¥ genetic instability ¥ aging ¥ nucleoplasmic local-
ization
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 syndrome (WS)
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 is an autosomal reces-
sive disorder causing symptoms of premature ag-
ing accompanied by rare cancers. Patients with
WS have a short stature, juvenile cataracts, atrophy of the
skin, graying and loss of hair, diabetes mellitus, arterio-
sclerosis, osteoporosis, and neoplasia (Werner, 1904; Ep-
stein et al., 1966; Martin, 1978; Goto et al., 1996). The
early appearance of these symptoms generally associated
with normal aging suggests that WS may represent an ac-
celerated aging, with a 2Ð2.5-fold faster rate than normal
aging. The life span of WS patients is 46 
 
6
 
 11.6 yr due
mainly to death caused by malignant tumor or cardiovas-
cular infarctions (Goto, 1997). In vitro studies on the
growth characteristics of fibroblast cells also suggest that
WS may be related to normal aging: the life span of WS
fibroblasts as expressed by population doubling levels
(PDL) is much shorter than that of normal fibroblasts
(Salk et al., 1985). We have already shown that the hyper-
mutator phenotype, such as genetic instability, also occurs
frequently in WS fibroblasts and lymphoblastoid B cells
(B cells) transformed by the Epstein-Barr virus (EBV;
Tahara et al., 1997).
The gene responsible for the WS (WRN) has been iden-
tified by positional cloning from the 8p11-12 region, and
encodes a DNA helicase belonging to a RecQ DNA heli-
case family (Yu et al., 1996). Defective DNA metabolism
is involved in a complex process of premature aging in WS
patients, because DNA helicases are enzymes that unwind
the energetically stable double-stranded structure of DNA
to provide the single-stranded template for important cel-
lular processes like replication, recombination and repair
(Lohman, 1993). Using an expression system with insect
cells and baculovirus, we and others previously demon-
strated that the WRN helicase gene indeed encodes a func-
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Abbreviations used in this paper:
 
 aa, amino acids; EBV, Epstein-Barr vi-
rus; EGFP, enhanced green fluorescent protein; NLS, nuclear localization
signals; PDL, population doubling levels; WS, WernerÕs syndrome. 
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tional DNA helicase that shows DNA-dependent ATPase
and DNA unwinding activities (Gray et al., 1997; Suzuki et
al., 1997). We also demonstrated that WRN helicase pro-
teins tagged either with NH
 
2
 
-terminal FLAG peptide or
enhanced green fluorescent protein (EGFP) localize ex-
clusively in the nuclei of HeLa cells, consistent with the
role of DNA helicase in nuclei (Matsumoto et al., 1997a;
Suzuki et al., 1997).
Mutations occurring in WS patients have been exten-
sively investigated by us and others with 
 
.
 
100 patients. To
date, 
 
z
 
20 different types of mutations have been identi-
fied that are distributed in the entire coding regions of the
WRN and exist in individual patients as either homozy-
gous or compound heterozygous mutations (Matsumoto
et al., 1997b; Oshima et al., 1997). More recently, we found
that most of these mutations generate truncated helicase
molecules lacking nuclear localization signals (NLS) in the
COOH-proximal region, rendering all WRN products un-
able to be transported to the nucleus where the DNA heli-
case is supposed to function (Matsumoto et al., 1997a;
Matsumoto et al., 1998a). Importantly, this finding clearly
explains why WS patients show a set of similar clinical
phenotypes no matter what type of mutation they carry.
Also, we found that both fibroblasts and EBV-trans-
formed B cell lines from patients with homozygous muta-
tion-4 or mutation-6, two of the most common mutation
types in Japanese WS patients, have much less WRN
mRNA than normal cells (Yamabe et al., 1997). This re-
duction in the WRN mRNA level suggests an augmented
specific degradation of the WRN mRNA in patient cells,
as was shown in other cases in which the nonsense codons
affect RNA metabolism in vertebrate cells (Maquat, 1995).
As regards the transcriptional regulation of WRN gene,
we have recently characterized the promotor activity and
found that the WRN gene expression is directed mainly by
the SP1 transcriptional control system, like that of other
housekeeping genes, but is further modulated by transcrip-
tional factors, including Rb and p53 (Yamabe et al., 1998).
In this study, we established several mouse mAbs spe-
cific to WRN helicase, and their epitope regions were de-
termined. With these defined antibodies, we investigated
the subnuclear distribution of endogenous WRN helicases
by immunocytochemical staining. In addition, the levels of
endogenous WRN helicase expression were compared for
the first time at the protein level for normal cells, trans-
formed cells and for tumor cells. Strikingly, the expression
level was highest for immortal EBV-transformed B cells,
followed by high levels for mortal EBV-transformed B
cells and a low level for untransformed B cells in the pe-
ripheral blood. Cellular WRN helicase levels determined
by mAbs for other tumor cell lines are discussed in rela-
tion to the potential biological function of WRN helicase
whose defects apparently result in chromosomal instability
in WS patient cells.
 
Materials and Methods
 
Cell Lines
 
Skin fibroblasts were obtained from human biopsy samples and cultured
by the method of Martin (1978); B cells were obtained by transforming
peripheral blood leukocytes with EBV (Miller, 1990). In brief, peripheral
blood leukocytes from normal individuals and WS patients were purified
using a Lymphocyte Separation Medium and were transformed by EBV
propagated in marmoset cell line B95-8 in the presence of 0.2 
 
m
 
g/ml Cy-
closporin (Sandoz). Established cell strains were cultured in 25-cm
 
2
 
 bot-
tles (Corning) using RPM11640 medium (Nissui Pharmaceutical Co. Ltd.)
supplemented with 10% fetal calf serum (GIBCO BRL). The WI38 cell
line originally from human embryonic lung fibroblasts and the WI38 line
transformed by SV-40 were donated by Dr. Ide (Hiroshima University).
Other cell lines were purchased from the American Tissue Culture Collec-
tion. All cell lines were maintained in RPMI 1640, McCoyÕs 5a medium or
DME supplemented with 10% heat-inactivated FCS. The cell lines were
cultured at 37
 
8
 
C in a humidified CO
 
2 
 
incubator.
 
Separation of Peripheral B-Lymphocytes
 
We used the panning method (Lewis and Kamin, 1980) to separate B-lym-
phocytes. In brief, leukocytes were collected from 20 ml peripheral blood
by centrifuging with a lymphocyte separation medium (Organotechnika)
following the instructions of the manufacturer and then suspended in PBS
containing 5% FCS, and were added to a polystyrene culture flask whose
surface had been coated with affinity-purified rabbit antiÐhuman immu-
noglobulin antibodies (Organotechnika). Leukocytes were kept for 1 h at
20
 
8
 
C. After removing nonadherent cells by decantation and washing five
times with PBS, the adherent B-lymphocytes were recovered from the sur-
face of the culture bottle by leaving the cells 15 min at 20
 
8
 
C in PBS con-
taining 4 mg/ml Lidocain-HCl and by subsequent pipetting. The periph-
eral blood B cells thus obtained were washed by PBS and were used for
Western blot analysis.
 
Immunization and Preparation of Hybridomas
 
To prepare an immunogen, the whole WRN helicase molecule that con-
tained NH
 
2
 
-terminal hexahistidine was produced in insect Sf21 cells with
baculovirus expression systems as described by Suzuki et al. (1997). The
expressed WRN helicase was purified to homogeneity by affinity column
chromatography using Ni-chelating NTA agarose gel (Qiagen Inc.). In ad-
dition, a recombinant partial fragment containing NH
 
2
 
-terminal hexahisti-
dine and the COOH-terminal half of WRN helicase consisting of amino
acid residues 877Ð1,432 was produced in 
 
E
 
.
 
 coli
 
, and was used as an immu-
nogen after purifying by affinity chromatography with NTA resin. Rat
mAbs specific to the mouse homologue of human WRN helicase were
made using the purified protein, containing NH
 
2
 
-terminal glutathione-
 
S
 
-transferase, and the COOH-terminal polypeptide fragment consisting
of amino acid residues 273Ð513 of mouse WRN helicase, which were made
in 
 
E
 
.
 
 coli
 
.
 
 
 
BALB/c mice and Wistar rats were, respectively, immunized
with these purified proteins in a complete FreundÕs adjuvant. Hybridoma
clones that produced the antigen-specific antibodies were screened by
ELISA and Western blot analysis.
 
Determination of the Epitope Regions in the WRN 
Helicase Molecule Recognized by mAbs
 
Various NH
 
2
 
- or COOH-terminal fragments of the WRN helicase protein
that were NH
 
2
 
-terminally tagged with EGFP were produced in mouse
melanoma cells B16F10 by transfecting a series of recombinant pEGFP-
C3 expression plasmids (Clontech Laboratories Inc.) that contained the
CMV promoter and the downstream DNA sequences coding for EGFP
and fragments of WRN helicase. For example, the C49 and C59 polypep-
tides that contain NH
 
2
 
-terminal EGFP and COOH-terminal fragments of
WRN helicase consisting of 49 aa and 59 aa, respectively, were generated
by placing the cognate DNA fragments coding for these polypeptides in
pEGFP-C3 plasmid downstream of the CMV promoter-EGFP sequence,
and were transiently expressed in B16F10 cells by transfecting the con-
structed recombinant plasmid DNA (Matsumoto et al., 1997a). The N368
polypeptide containing the NH
 
2
 
-terminal 368 aa was similarly produced in
B16F10 cells. Expression plasmids coding for other EGFP-conjugated
proteins, N1304, N1162, N1046, C138, C128, C79, C69, and C19, were
similarly constructed and were expressed in B16F10 cells. Cells express-
ing these polypeptides were fixed as described above in the immunocy-
tochemistry section and were stained with the mAbs conjugated with fluo-
rescent reagent Texas red. To define the epitope sites more precisely for
mAbs to recognize the NH
 
2
 
-terminal region of WRN helicase, a recombi-
nant partial fragment (C1201) containing NH
 
2
 
-terminal hexahistidine, but
with no NH
 
2
 
-terminal 231 aa, was synthesized and was used for Western
blot analysis after purification by Ni-NTA column chromatography. 
Shiratori et al. 
 
Expression and Nucleoplasmic Localization of WRN Helicase
 
3
 
Immunoblot Analysis
 
Cell lysates were prepared as described by Tada et al. (1996) from subcon-
fluent cultures of cells. Approximately 10
 
7
 
 cells were washed with ice-cold
PBS, pelleted and disrupted in RIPA buffer containing 10 mM Tris-HCl
buffer (pH 7.4), 1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 150
mM NaCl, 1 mM ethylene diamine tetra acetate and a cocktail of protease
inhibitors (PharMingen), and a portion of cell lysate containing 20 
 
m
 
g pro-
tein (derived from 
 
z
 
1.5 
 
3
 
 10
 
5
 
 fibroblast cells and 2.2 
 
3
 
 10
 
5
 
 lymphoblas-
toid B cells) was electrophoresed on 7% SDSÐpolyacrylamide gels. A
prestained SDS-PAGE standard protein marker (Bio-Rad Laboratories
Inc.) was used to calibrate the molecular mass; it contained myosin (213
kD), 
 
b
 
-galactosidase (119 kD), BSA (83 kD), and ovalbumin (47 kD).
Proteins resolved in gel were electrophoretically transferred to a polyvi-
nylidene difluoride membrane, Immobilon (Millipore). The transferred
membrane was treated with TBS (20 mM Tris-HCl, 150 mM NaCl, pH
7.5) containing 5% (wt/vol) skim milk for 1 h. The membrane was then in-
cubated overnight at 4
 
8
 
C with diluted antibodies to determine the specific-
ity and affinity to WRN helicase of the antibodies. The membrane was
washed and then was incubated with anti-mouse IgG-conjugated HRP
(Dako). After washing again, the membrane was developed using ECLª
(Amersham Life Science, UK).
 
Immunocytochemistry by Indirect Immunofluorescence
 
Cells were grown to 
 
z
 
80% confluency in 100-mm tissue culture dishes
(Corning) and were stuck onto a silane-coated slide by cytospin. The
spread cells were immediately fixed with 3.7% formaldehyde in PBS for
10 min and washed and permeabilized with PBS containing 0.05% Tween
20 (washing buffer). They were then treated with 3% (wt/vol) skim milk in
PBS at room temperature for 2 h, treated with 0.1% Triton X-100 in PBS,
and incubated with mouse anti-WRN helicase mAbs as the primary anti-
bodies overnight at 4
 
8
 
C. The cells were washed again with the washing
buffer three times for a total of 30 min, and they were further incubated
with biotinylated goat antiÐmouse IgG
 
1 
 
(Southern Biotechnology Associ-
ates Inc.) for 1 h at room temperature. The cells were washed again with
the washing buffer and incubated with 5 
 
m
 
g/ml streptavidin FITC (Phar-
Mingen) for 30 min at room temperature.
Double immunocytostaining was made for WRN helicase and the nu-
cleolus protein using mouse mAb 8H3 and the goat polyclonal antibody
B23 (Santa Cruz) specific to nucleolar nucleophosmin/B23 protein as pri-
mary antibodies. These antibodies were mixed and incubated with the
fixed HeLa cells. As secondary antibodies, the biotinylated donkey antiÐ
mouse IgG and the Cy3 conjugated donkey antiÐgoat IgG (both from
Chemicon International) were used to detect the primary antibodies that
bound to WRN helicase and the nucleolus protein. The Cy3-conjugated
IgG emitted red fluorescence, while the biotinylated antiÐmouse IgG was
stained green by streptavidin FITC by the same conditions described
above. The nuclei were counterstained blue with DAPI. Fluorescent im-
ages were visualized with a Bionanoscope (Nikon Engineering) fitted with
a 100
 
3
 
 Nikon PlanApo oil immersion objective and two double-pass filter
sets for fluorescein/DAPI and Texas red. An alternative procedure using
acetone-methanol (1:1 vol/vol) was also carried out, which resulted in sim-
ilar staining profiles (data not shown).
 
Determination of Subnuclear Distribution of WRN 
Helicase by Expression of the Full-Size cDNA in
HeLa Cells
 
An expression plasmid was constructed with the full-size WRN cDNA
and pEGFP-C3 plasmid (Clontech). The cloned full-size cDNA was
placed downstream of the EGFP sequence in the pEGFP-C3 DNA, ac-
cording to the manufacturerÕs instruction. It was transfected to HeLa cells
and the WRN helicase NH
 
2
 
-terminally tagged with EGFP was generated
as described before (Matsumoto et al., 1997a). HeLa cells were seeded
onto a poly-
 
L
 
-lysine-coated cover glass (Iwaki Co.), cultured overnight
and then transfected with 5 
 
m
 
g of expression plasmid DNA mixed with 10 
 
m
 
g
lipofectin (GIBCO BRL). 24 h after transfection at 37
 
8
 
C, the cells were
fixed with 4% paraformaldehyde. A cover glass was mounted with 0.2 
 
m
 
g/ml
DAPI in antifade solution (Wako). The EGFP fusion proteins and nuclei
were visualized by fluorescence microscopy with a Nikon Optiphot-2 mi-
croscope fitted with a 60
 
3
 
 Nikon PlanApo oil immersion objective and a
triple-pass filter set for fluorescein/DAPI and Texas red. Fluorescent im-
ages were collected using a high performance CCD camera and were pro-
cessed by MacProbe (Perceptive Scientific Instruments).
 
Results
 
Preparation of mAbs Specific for WRN Helicase and 
Epitope Mapping
 
After screening multiple independent clones of hybridoma
cells, we found five hybridoma cell lines generating the
isotypes of mouse IgG
 
1
 
k
 
,
 
 referred to hereafter as 3D12,
4H12, 4D9, 4F8, and 8H3, that bind efficiently in immuno-
blot analysis to whole molecules of purified WRN helicase
(Fig. 1). Their epitopes were determined by measuring the
immunoreactivity of mAbs to parts of the WRN helicase
generated by expression of the fragments of WRN cDNA
in B16F10 mouse melanoma cells (Table I). The B16F10
cells express a very low level of endogenous murine WRN
helicase protein (our unpublished data), and therefore do
not disturb the detection of binding between mAbs and
the recombinant derivatives of human WRN helicase ex-
pressed in the cells. The derivatives of human WRN heli-
case contained NH
 
2
 
-terminal EGFP and various lengths of
fragments of WRN helicase (aa residues 1Ð368, 1Ð1,046,
1Ð1,162, 1Ð1,304, 1,294Ð1,432, 1,304Ð1,432, 1,353Ð1,432,
1,363Ð1,432, 1,373Ð1,432, 1,383Ð1,432, and 1,413Ð1,432). A
convenient color reaction was used to assess the epitopes
of each mAbs; the location of expressed fusion proteins
were shown by green fluorescence, and positive immuno-
reactions between fusion proteins and mAbs were shown
by a red color due to Texas redÐconjugated avidin that
binds to biotinylated antiÐmouse IgG (Fig. 2). mAb 4H12
was found to react with COOH-terminal polypeptide C59
consisting of 59 aa residues but not to a shorter COOH-
terminal polypeptide C49 consisting of 49 aa residues, in-
dicating that the epitope of 4H12 is in the 10 aa residues
that C49 lacks (Fig. 2 A)
 
.
 
 This 10-aa region contains the
NLS required for WRN helicase to migrate from the cyto-
plasm to the nucleus (Matsumoto et al., 1997b). The mAbs
4D9, 4F8, and 8H3 could bind to the N368 polypeptide
containing the NH
 
2
 
-terminal 368 aa residues of WRN heli-
case (Fig. 2 B shows the data obtained with mAb 8H3).
The epitopes of 4D9, 4F8, and 8H3 were further narrowed
by immunoblot analysis to a NH
 
2
 
-proximal region be-
tween amino acid residues 232 and 368 after examining
their binding activities to a mutant WRN helicase (C1201)
that lacked NH
 
2
 
-terminal aa residues 1Ð231 (Fig. 2 C).
Figure 1. Immunoblot analy-
sis of mAbs specific for WRN
helicase. WRN helicase (0.74
mg) produced in insect cells
by a baculovirus system and
purified by Ni-chelate column
chromatography (Suzuki et
al., 1997) was used for immu-
noblot analysis to monitor the
quality of mAbs. Lane 1,
Coomassie brilliant blue
stained WRN helicase; lanes
2 and 3, mAbs 3D12 and 4H12 raised against COOH-proximal
polypeptide (aa residues 877Ð1,432), respectively; lane 4, mAb
4D9 raised against full-size WRN helicase; lane 5, mAb 4F8
raised against full-size WRN helicase; lane 6, mAb 8H3 raised
against full-size WRN helicase. An arrow head shows the posi-
tions of full-size WRN helicase. 
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This region is downstream of the 3
 
9
 
-5
 
9
 
 exonuclease region
(60Ð231 aa residues) predicted by Mushegian et al. (1997)
from their homology search studies. The mAb 3D12
bound to recombinant WRN helicase proteins encompass-
ing the helicase domain and the COOH terminus (877Ð
1,432 aa residues), suggests that its epitope is on the
COOH-terminal side. Table I summarizes these results.
Two mAb, 8H3 and 4H12, that recognize distinct epitopes
on WRN helicase at NH
 
2
 
-terminal 232Ð368 aa and
COOH-terminal 1,373Ð1,432 aa, respectively, were mainly
used for the following studies.
 
Detection of WRN Helicase Molecules in Fibroblasts 
and EBV-transformed B-Lymphoblastoid Cells from 
Normal Individuals
 
To detect endogenous WRN helicase in fibroblast cells
from normals and WS patients, we first carried out an im-
munoblot analysis using mAb 4H12 that has the epitope in
the COOH-terminal region of the WRN helicase. Fig. 3 A
shows that mAb 4H12 detected WRN helicase with a mo-
lecular mass of 180 kD in the cell lysates prepared from
normal individuals (lanes 3 and 4). As expected, no spe-
cific band to WRN helicase was seen in the patient cell ly-
sates from homozygous gene mutation type 4/4 that yields
a truncated protein (1Ð1,060 aa) lacking the epitope of
4H12 (lanes 1 and 2). To find out if this immunological
detection extends to more easily obtainable EBV-trans-
formed B cells, we used immunoblot analysis for B cells
from two WS patients and two normals using mAb 8H3
that has an epitope in the NH
 
2
 
-terminal region (Fig. 3 B).
Like fibroblast cells, the cell lysate of B cells from normal
individuals showed a clear band of 180 kD WRN helicase
(lanes 3 and 4). In contrast to a clear visualization of WRN
helicase in the cell lysate prepared from the cells of normal
individuals, we found no sign of immunoreactive WRN he-
 
Table I. Determination of Epitopes of mAbs Specific for
WRN Helicase
 
WRN proteins Residues (aa)
mAbs
3D12 4H12 4D9 4F8 8H3
 
Western blotting
Full 1Ð1,432
 
s s sss
 
C1201 232Ð1,432
 
2
 
s sss
 
C600 833Ð1,432
 
ss
 
333
 
Immunostaining
Full 1Ð1,432
 
s s sss
 
N1304 1Ð1,304
 
332
 
s
 
2
 
N1162 1Ð1,162
 
232
 
s
 
2
 
N1046 1Ð1,046
 
33
 
sss
 
N368 1Ð368
 
32
 
sss
 
C138 1,294Ð1,432
 
3 2 222
 
C128 1,304Ð1,432
 
3
 
s
 
232
 
C79 1,353Ð1,432
 
3
 
s
 
232
 
C69 1,363Ð1,432
 
3
 
s
 
222
 
C59 1,373Ð1,432
 
3
 
s
 
222
 
C49 1,383Ð1,432
 
3 3 222
 
C19 1,413Ð1,432
 
3 3 232
 
Results obtained by immunoblot analysis and immunostaining are summarized. The
WRN proteins having various amino acid residues are shown in the two left columns;
C and N stand for COOH and NH
 
2
 
 termini of intact WRN helicase. The open circles
show positive immunoreactivity, while the crosses show no reactivity. The horizontal
bars indicate that experiment was not done.
Figure 2. Determination of the epitopes of mAbs 4H12 and 8H3
that recognize COOH- and NH2-terminal region of WRN heli-
case. (A) The epitope of mAb 4H12 was determined using the
parts of WRN helicase, C59 (COOH-terminal 59 aa) and C49
(COOH-terminal 49 aa), expressed as a fusion protein with
EGFP in B16F10 mouse melanoma cells. The cells were fixed
and tested for immunostaining by mAb 4H12, which was conju-
gated with fluorescent reagent Texas red (right). DAPI stains
DNA and shows the location of the nucleus (left) and EGFP
(middle) shows the locations of expressed EGFP fusion proteins.
C59 contains the nuclear localization signal NKRRCF at aa resi-
dues 1,369Ð1,402 (Matsumoto et al., 1997a; Matsumoto et al.,
1998a) and localizes in the nucleus, while C49 lacks the nuclear
localization signal and does not migrate to the nucleus. (B) The
epitope of mAb 8H3 was determined as for 4H12. The NH2-ter-
minal fragment N368 (NH2-terminal 368 aa) was expressed in
B16F10 cells as an EGFP-fused form and was tested for immuno-
staining with Texas redÐconjugated mAb 8H3. The EGFP-N368
fusion protein does not have NLS and localizes in the cytoplasm
of B16F10 cells. (C) Further epitope analysis of mAb 8H3 was
made by Western blot analysis. Here, a full-size WRN helicase
(lane 2) and a C1201-WRN helicase lacking NH2-terminal 231 aa
synthesized by a baculovirus system (lane 1) were resolved by
SDS-PAGE in 7% polyacrylamide gel and stained by Coomassie
brilliant blue. They were blotted to filter and were tested for im-
munoreactivity with mAb 8H3 (lanes 3 and 4). (D) Schematic
representation of WRN helicase molecule and the epitope sites
for mAbs. 
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5
 
licase-specific polypeptide in the cell lysates from WS pa-
tients carrying a homozygous mutation 4 (lanes 1 and 2).
The amount of WRN helicase protein in 20 
 
m
 
g lysate pro-
tein of B cells was greater than that of fibroblast cells, as
estimated from the intensities of the stained bands in im-
munoblot analysis.
 
Upregulation of the Expression of WRN Helicase by 
Transformation and Immortalization
 
The expression levels of the WRN gene product in fibro-
blasts derived from normal individuals were about one-
tenth of those of EBV-transformed B-lymphoblastoid cells
(Fig. 3). To gain more information about the levels of
WRN helicase protein in various cells, we compared the
levels of WRN helicase protein for the WI38 human dip-
loid cell line derived from embryonic lung and the same
WI38 cells transformed with SV-40. Comparative immu-
noblot analysis showed that the SV-40-transformed WI38
cells (WI38/SV) contained a higher level (
 
z
 
10-fold) of
WRN helicase protein than the original WI38 cells (Fig. 4
A, lanes 1 and 2). The level in WI38/SV cells was compara-
ble to or slightly greater than that in HeLa cells (lane 3).
The transformation of B cells by EBV can only extend
the life span of most B cells up to a maximum 160 PDLs
and does not necessarily make the cells immortal, as op-
posed to an often misunderstood concept that EBV infec-
tion makes B cells immortal (Tahara et al., 1997). How-
ever, a few populations of immortal B cells occur after a
long period of culture of transformed B cells, similar to fi-
broblast cells transformed by SV-40. In our laboratory,
three such immortalized B-lymphoblastoid cell lines were
established from B cells transformed by EBV originally
from normal individuals after a long period of culture, and
the cells showed strong telomerase and infinitely prolifer-
ating activities (Kataoka et al., 1997). About twofold
higher levels of WRN helicase were observed with these
immortalized B cells (Fig. 4 B, lanes 4 and 6) than with
their parental cells, which were mortal (lanes 3 and 5). In
a separate comparative study, we examined the level of
WRN helicase in untransformed B cells purified from pe-
ripheral blood cells, but no WRN helicase protein was de-
tected (Fig. 4 B, lanes 1 and 2). Here, the order of WRN
helicase expression was (a) immortal EBV-transformed
B cells with telomerase activity, (b)
 
 
 
mortal EBV-trans-
formed B cells with no or very low telomerase activity, (c)
untransformed B cells in peripheral blood. The data ob-
tained with B cells predict that tumor cells may have
Figure 3. Immunoblot analysis for
the amounts of WRN helicase in fi-
broblasts and B cells from WS pa-
tients and normal individuals. (A)
Cell lysates containing 20 mg pro-
tein were prepared from fibroblast
cells from patient (lanes 1 and 2)
and normals (lanes 3 and 4), and
were analyzed by Western blot
analysis with mAb 4H12 that recog-
nizes the COOH-terminal portion
of WRN helicase. Lane 1, lysate
from WS patient no. 15501 cells
(PDL 14) containing homomuta-
tion type 4/4; lane 2, lysate from an-
other WS patient no. 10801 cell
(PDL 24) containing homomuta-
tion type 4/4; lane 3, lysate from
normal no. TM36 cells (PDL 20);
lane 4, lysate from normal primary
cultured cell line WI38 (PDL 24).
Arrow head indicates the position
of 180-kD WRN helicase. Asterisks indicate the proteolytic deg-
radation products of WRN helicase that also react with mAb
4H12. (B) Immunoblot analysis was made for EBV-transformed
B cells from WS patients and normals as for A, but with mAb
8H3 that recognizes NH2-terminal 232Ð368-aa region. Lane 1,
WS patient no. 2101 cell (PDL 53) containing homomutation
type 4/4; lane 2, WS patient no. 10801 cells (PDL 36) containing
homomutation type 4/4; lane 3, normal individual no. 0003 cells
(PDL 53); lane 4, normal individual no. 0005 cells (PDL 18). Ar-
rowhead indicates the position of 180-kD WRN helicase.
Figure 4. Comparison of levels of WRN helicase expression in
cells of normal, transformed and immortal states. Immunoblot
analyses were made for 20 mg cell lysate proteins prepared from
various cells, including fibroblasts and B cells, of normal, virus-
transformed and immortal states. (A) Lane 1, normal WI38 cells;
lane 2, WI38 cells transformed with SV-40; lane 3, HeLa cells.
Arrowhead indicates the position of 180-kD WRN helicase, and
the asterisks show the proteolytic degradation products of WRN
helicase that also react with mAb 4H12. (B) Lanes 1 and 2, un-
transformed B cells from peripheral blood of normal individuals;
lane 3, mortal EBV-transformed B cells from normal individual
no. 0003 cells (PDL 53); lane 4, immortal B cells (PDL 269) de-
veloped from normal individual no. 0003 B cells; lane 5, mortal
EBV-transformed B cells from normal individual no. 0005 cells
(PDL 18); lane 6, immortal B cells (PDL 269) developed from no.
0005 B cells. (C) Comparison of expression levels of WRN heli-
case in tumor cell lines. Cell lysate proteins (20 mg) prepared
from various human tumor cell lines were analyzed for WRN he-
licase by Western blot analysis with mAb 4H12. Lane 1, HeLa
cells; lane 2, HT1080 cells (fibrosarcoma); lane 3, PA1 cells (ova-
rian teratocarcinoma); lane 4, Tera2 cells (embryonic carci-
noma); lane 5, T24 cells (bladder carcinoma); lane 6, K562 cells
(chronic myelogenous leukemia); lane 7, Molt4 cells (acute lym-
phoblastic leukemia); lane 8, A172 cells (glioblastoma). 
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higher levels of WRN helicase, as they are transformed
and immortalized from original normal progenitor cells.
 
WRN Helicases in Tumor Cells
 
The expression levels of WRN helicase were compared in
several human tumor cell lines by comparative immuno-
blot analysis with mAb 4H12 that recognizes the COOH-
terminal epitope. All human tumor cell lines examined
showed a level equivalent to that in HeLa cells or higher
levels (Fig. 4 C). These cell lines were HT1080 (fibrosar-
coma), PA1 (ovarian teratocarcinoma), Tera2 (embryonic
carcinoma), T24 (bladder carcinoma), K562 (chronic my-
elogenous leukemia), Molt4 (acute lymphoblastic leuke-
mia), and A172 (glioblastoma) cells, and are shown in
lanes 2, 3, 4, 5, 6, 7 and 8, respectively (Fig. 4 C). The high-
est expression was found in K562 cells that showed much
higher activity than that of HeLa cells (lane 6) followed by
PA1, Tera2, and Molt4 cells (lanes 3, 4, and 7). The molec-
ular size of WRN helicase was unaltered and remained at
180 kD for all tumor cells examined.
 
Immunocytochemistry Showing the Location of WRN 
Helicase in the Nucleoplasm
 
We used mAbs to determine the subnuclear location of
Figure 5. Determination of
subnuclear distribution of
WRN helicase by immunocy-
tochemical staining and ex-
pression of a full-size WRN
cDNA. (I) Subnuclear distri-
bution of endogenous WRN
helicase was examined by in-
direct immunocytochemical
staining with mAb 4H12 for
fibroblast cells from normal
donors and WS patient no.
15501, and for Tera2 and
WI38/SV cells. For controls,
the nucleoli of normal fibro-
blast, WS patient no. 15501
and Tera2 cells were stained
separately by mAb, anti hu-
man nucleolus clone AE3
(Leinco Technology Inc.),
specific for human nucleolus.
The nuclei of these cells were
also stained by DAPI. (A and
B) Fibroblast cells (inter-
phase) from normal individ-
ual stained by DAPI and
4H12 antibody, respectively.
(C and D) Fibroblast cells
(interphase) from normal in-
dividual stained by DAPI and
anti-nucleolus antibody, re-
spectively. (E and F) Fibro-
blast cells (interphase) from
WS patient no. 15501 con-
taining homomutations 4/4
stained by DAPI and 4H12
antibody, respectively. (G
and H) Fibroblast cells (inter-
phase) from WS patient no.
15501 containing homomuta-
tions 4/4 stained by DAPI
and anti-nucleolus antibody,
respectively. (I and J) Tera2
cells (interphase) stained by
DAPI and 4H12 antibody re-
spectively. (K and L) Tera2
cells (interphase) stained by
DAPI and anti-nucleolus an-
tibody, respectively. (M and N) Tera2 cells chromatins from the metaphase stained by DAPI and 4H12 antibody, respectively. (O and
P) WI38/SV cells (interphase) stained by DAPI and 4H12 antibody, respectively. (Q and R) Mouse colon 26 cells stained by DAPI and
rat mAb to mouse WRN protein, respectively. (II) Subnuclear distribution in HeLa cells of WRN helicase synthesized as fusion protein
with EGFP. (A) The DAPI stained HeLa cell nuclei. (B) The EGFP-human WRN helicase expressed in HeLa cells. 
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WRN helicase. Previously, we showed that WRN helicases
expressed in HeLa cells by transfected expression plas-
mids migrate exclusively to the nucleus (Matsumoto et al.,
1997a; Suzuki et al., 1997). This nuclear migration was
found to be dependent on the NLS encoded in the COOH-
terminal region of WRN helicase (Matsumoto et al.,
1998a). However, where in the nucleus WRN helicases re-
side, and whether the location changes upon cell cycling,
remained unclear. To define the subnuclear location, we
immunocytochemically stained the endogenous WRN he-
licase in skin fibroblasts from a normal individual (Fig. 5 I,
A and B), skin fibroblasts from a WS patient (E and F),
Tera2 cells (I and J), and WI38/SV cells (O and P). All the
results showed that WRN helicase was mainly located in
the nucleoplasm. In these cells the nucleolus regions were
left unstained and were represented by black holes (Fig. 5
I, J and P). A higher magnification of the immunostaining
of Tera2 cells by mAb 4F8 showed that the stained WRN
helicase antibody exists as multiple nuclear dots (Fig. 6).
Similar profiles were obtained by other mAbs 3D12, 8H3,
and 4D9. To avoid the possibility that nucleolus proteins
might be leaked by disruption of nucleoli during our im-
munocytostaining, as a reference, we stained the cells sim-
ilarly with a different anti-human nucleolus antibody AE3
that has been broadly used to stain specifically the nucleo-
lus. However, this was not the case, as shown in Fig. 5 I (C
and D, G and H, and K and L for normal fibroblast, WS fi-
broblast and Tera2, respectively) in which the nucleoli of
these cells were stained distinctly by the nucleolus-specific
antibodies. When mouse colon carcinoma cells (colon 26)
were stained with a rat monoclonal antibody specific to
the mouse WRN helicase, again only the nucleoplasm was
stained (Fig. 5 I, Q and R), indicating that the major part
of WRN helicase is in the nucleoplasm and not in the nu-
cleoli for both human and mouse cells.
To confirm the nucleoplasmic localization of WRN heli-
case, we made a double immunostaining of growing HeLa
cells using a mixture of two antibodies, mouse mAb 8H3
specific to WRN helicase and goat polyclonal antibody
B23 specific to the nucleolar protein nucleophosmin/B23.
The WRN helicase was simultaneously stained green using
FITC and the nucleolus protein red using Cy3 (Fig. 7, 2
and 3). Under the conditions described in Materials and
Methods, whole HeLa nuclei were stained blue by DAPI
(which stains DNA), leaving several nucleolar regions un-
stained (Fig. 7, 1). The green WRN helicase signals spread
in the entire nucleus consistent with a localization of WRN
helicase mainly in nucleoplasm (Fig. 7, 2), while the red
B23 signals were restricted in the nucleolar regions that
were unstained by DAPI (Fig. 7, 3). The overlaid picture
(Fig. 7, 4) showed that the nucleolar regions were dis-
tinctly stained with red/orange, and the surrounding nucle-
oplasm was stained with green, indicating nonoverlapping
of WRN helicase and the nucleolar nucleophosmin/B23.
These double immunocytostaining data confirmed our
conclusion that the WRN helicase is mainly in the nucleo-
plasm of growing HeLa cells and not in the nucleolus.
Previously, we expressed the full-size WRN cDNA in
HeLa cells to generate the WRN helicase NH
 
2
 
-terminally
tagged with EGFP or FLAG. The expressed FLAG-WRN
helicases localized in the entire nucleus of HeLa cells (Su-
zuki et al., 1997 [Fig. 2 therein]). In a similar experiment,
the expressed EGFP-WRN helicases also localized in the
nucleus (Matsumoto et al., 1997a), with a notable exclu-
sion from small regions that presumably are nucleolus
(Fig. 5 I, I). The results of these experiments are consistent
with a conclusion of this paper that the WRN helicases
mainly exist in the nucleoplasm.
To find out if WRN helicase exists in the condensed
chromatin at metaphase, we analyzed the distribution of
WRN helicase in Tera2 cells stained during their meta-
phase; however, we were unable to detect WRN helicase
on the condensed chromatin (Fig. 5 I, M and N). These
data indicate that WRN helicase is distributed in the nu-
cleoplasm, not in the nucleoli or on the condensed chro-
matin at the metaphase.
Figure 6. A magnified profile
of immunostained WRN heli-
case in the nucleoplasm. WRN
helicases in Tera2 cells were
immunostained by mAb 4F8
at the interphase of cell cycle.
The green fluorescent dots
demonstrate WRN helicase,
and the black holes within
the stained cell correspond to
the nucleoli. Bar, 10 mm. 
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Discussion
 
The gene, its product DNA helicase and various gene mu-
tations responsible for Werner syndrome have been iden-
tified. Our previous findings that defective WRN helicase
in patient cells are unable to migrate to the nucleus be-
cause of a lack of COOH-terminal NLS also explains why
patients with WS show similar clinical phenotypes regard-
less of the type of gene mutation. Despite this fundamen-
tal knowledge of the pathogenesis of WS, several impor-
tant issues concerning the endogenous protein level of
WRN helicase in normal cells or cells of various states and
its precise subnuclear location remained unknown. This
report clarifies some of these issues.
 
Diagnosis of Werner Syndrome by Immunoblot Analysis
 
In this study, two types of mAb recognizing the NH
 
2
 
-
or COOH-terminal region of WRN helicase were estab-
lished. We used these antibodies in Western blot analysis
to make the immunological diagnosis of WS possible by
analyzing the lysates of cells from patients and normal in-
dividuals. The WS patients with mutation type-4, the most
frequent WRN mutation in the world, can be diagnosed
immunologically by the absence of WRN helicase protein
in EBV-transformed B cell lysates (Fig. 3). Recently, we
developed two types of genetic diagnosis systems, mutant
allele specific amplification and oligonucleotide ligation
assay that use the nucleotide sequence information of mu-
tated genes and PCR (Matsumoto et al., 1998b). However,
because such a genetic diagnosis is made from only known
mutated gene sequences and their specific primer settings,
they can not be used for WS with unknown mutations. To
detect truncated gene products or the absence of gene
products, the immunological method using mAbs with a
refined epitope, as is shown for WS in this report, will lead
the way to the clinical field in combination with a genetic
diagnosis. Most WRN mutations result in the generation
 
of truncated proteins, and therefore, the absence of a 180-kD
full-size WRN helicase molecule in EBV-transformed B
cells from patients will indeed indicate WS. Previously, we
reported that the levels of mutant WRN mRNA in WS pa-
tient cells are significantly lower (average 16%) than those
of intact mRNA from normal individuals (Yamabe et al.,
1997), and we anticipated a low level of truncated WRN
gene products in WS patient cells. The results obtained
from patient cell lysates by immunoblot analysis were be-
yond this anticipation, because the patient cells (with ho-
mozygous mutation 4) showed almost no detectable trun-
cated WRN helicase molecules with predicted size of 120 kD.
Our more extended studies showed that cells from WS pa-
tients carrying homozygous mutations 6, 7, and 9 also
contained no mutant proteins in the predicted truncated
forms of 40, 130, and 70 kD, respectively (data not shown).
We speculate that the truncated WRN helicase molecules
may be sensitive to cellular proteases, and may be re-
moved from WS patient cells by proteolytic digestion. A
slightly larger molecular mass (180 kD) of endogenous
WRN helicase than the predicted 162 kD was observed for
all cells used in this study. Whether this larger molecular
mass is due to phosphorylation and/or other post transla-
tional protein modifications should be investigated.
 
WRN Helicase Gene Expression Is Upregulated in 
Rapidly Proliferating Cells
Our findings that the copy number of WRN helicase is
markedly augmented in EBV-transformed B cells or SV-
40-transformed fibroblasts apparently provide an impor-
tant foresight into the role of WRN helicase in these cells
that have acquired a rapidly proliferating phenotype. To-
day, whether the transformation by viruses fortuitously
stimulates the transcription and translation of WRN, or
whether the cells that proliferate fast require a high level
of WRN helicase and thus such cells with a large copy
number of WRN helicases are selected, is not clear. The
latter hypothesis is plausible because all the tumor cell
lines that are free from virus infection and proliferate rap-
idly showed high levels of WRN expression (Fig. 4 C). In
this context, we recently found the transcription of WRN
helicase gene is regulated by several SP1 and a RCE ele-
ments, characteristic of a housekeeping gene, but is fur-
ther modulated by tumor suppressor Rb and p53 proteins:
upregulation by Rb and downregulation by p53 (Yamabe
et al., 1998). The high levels of WRN helicase in tumor
cells observed in this study may be due to the combined ef-
fects of the increased Rb and the inactivation of p53 by
mutation. Perhaps, greater numbers of WRN helicase may
Figure 7. Double immunocytochemical staining of WRN helicase and the nucleolus protein of growing HeLa cells. Experimental condi-
tions were described in Materials and Methods. (1) HeLa cell nuclei stained blue with DAPI. The unstained dark areas show the nucle-
oli. (2) WRN helicases (green) detected in nucleoplasm. (3) Nucleophosmin/B23 protein (red) detected in nucleoli. (4) Overlaid profile
of stained WRN helicase (2) and nucleophosmin/B23 (3). The red/orange areas match with the nucleolus regions shown in panel 1.Shiratori et al. Expression and Nucleoplasmic Localization of WRN Helicase 9
be needed for some rapidly growing cells to suppress the
genomic instability resulting from the illegitimate recom-
binations incurred by the continual DNA replications.
Supporting this hypothesis, we recently showed that WRN
gene can suppress the increased homologous and illegiti-
mate recombination of Saccharomyces cerevisiae mutant
cells that lack the Sgs1 DNA helicase belonging to the
RecQ helicase family (Yamagata et al., 1998).
WRN Helicases Are Distributed as Nuclear Dots in the 
Nucleoplasm and Are Not in the Condensed Chromatin
Our immunocytochemical studies clearly showed that WRN
helicases are distributed in the nucleoplasm during the in-
terphase, and are not in the condensed chromatin in the
metaphase (Fig. 5 I, M and N). Marciniak et al. (1998), us-
ing polyclonal antibodies, showed that WRN helicase lo-
calizes in the nucleolus of WI38 cells, whereas the mouse
WRN helicase is distributed in the nucleoplasm. Their
data on the location of human WRN helicase, therefore,
contradict the findings of this study. This discrepancy does
not seem to stem from the methods used for fixing cells
because we obtained unambiguous nucleoplasmic staining
for WI38 and WI38/SV cells after fixation with the ace-
tone-methanol method that Marciniak used. The condi-
tions of the cultured cells, e.g., growing or nongrowing, or
the extent of cell confluence, may rather affect the mode
of nuclear localization. These important issues remain to
be clarified by the specific and refined antibodies charac-
terized in this study. In this context, the fact should be
mentioned that the commercially available polyclonal an-
tibody (sc-1956; Santa Cruz) produced a similar result as
our mAbs.
Our findings described in this paper are also dissimilar
to previous observations obtained with yeast sgs1 helicase,
a homologue of WRN helicase in S. cerevisiae, in which
sgs1 exists in the nucleolus when the cells are young and
migrates to the nucleoplasm as the cells senesce and the
nucleoli fragment (Sinclair et al., 1997). Rather, the pro-
files of immunostaining of WRN helicase shown in this re-
port resemble those of p53 and RF-A (replication factor
A) that bind to DNA exclusively in the nucleoplasm (Din
et al., 1990; Wilcock and Lane, 1991). Further studies are
needed to determine if yeast sgs1 has the same biological
role as human WRN helicases in DNA metabolism. In ad-
dition, most importantly, the kind of DNA event(s) where
WRN helicase fails to participate in patient cells remains
to be clarified.
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